Surfing NASH offered on-site coverage of EASL Congress 2023 in two separate real-time reviews. This conversation continues from the first session featuring Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green and their focus on the first three days of the meeting.
The group begins by discussing the Friday afternoon session that Jörn co-chaired which investigates the challenges in screening patients for fatty liver diseases. One issue that surfaces is the dynamic tension around time that frontline treaters in the UK grapple with between conducting multi-stage sequential screening and supporting behavioral interventions adequately. It is suggested that they are concerned with not being able to deliver on both of these critical aims without compromise. The conversation shifts to focus on the Friday morning session on therapies which were described as the second wave of NASH drugs. This includes discussion around two dual agonists, efinopegdutide and pemvidutide, that could achieve what Ian describes as “huge reductions” in liver fat. The group goes on to touch on two other presentations from that session, one covering the impact of intermittent fasting on the liver versus standard calorie reduction, the other on reporting results on an RNA-based product.
For a variety of reasons the entire community looks forward to this meeting with an unprecedented sense of intensity and excitement. These seven conversations suggest that the actual event met or exceeded such high expectations – listen on to learn how and why and stay tuned for Part 2 of this exclusive coverage. If you have any question or interests around EASL Congress, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!